Musharaf I, Nashwan AJ. Association of interleukin-6 with acute lung injury risk and disease severity in sepsis. World J Clin Cases 2025; 13(8): 98379 [DOI: 10.12998/wjcc.v13.i8.98379]
Corresponding Author of This Article
Abdulqadir J Nashwan, MSc, PhD, Research Scientist, Department of Nursing and Midwifery Research, Hamad Medical Corporation, Rayyan Road, Doha 3050, Qatar. anashwan@hamad.qa
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Mar 16, 2025; 13(8): 98379 Published online Mar 16, 2025. doi: 10.12998/wjcc.v13.i8.98379
Association of interleukin-6 with acute lung injury risk and disease severity in sepsis
Imshaal Musharaf, Abdulqadir J Nashwan
Imshaal Musharaf, Department of Medicine, Jinnah Sindh Medical University, Karachi 75510, Pakistan
Abdulqadir J Nashwan, Department of Nursing and Midwifery Research, Hamad Medical Corporation, Doha 3050, Qatar
Author contributions: Musharaf I and Nashwan AJ writing the draft and critically reviewing the literature.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abdulqadir J Nashwan, MSc, PhD, Research Scientist, Department of Nursing and Midwifery Research, Hamad Medical Corporation, Rayyan Road, Doha 3050, Qatar. anashwan@hamad.qa
Received: June 25, 2024 Revised: November 4, 2024 Accepted: November 26, 2024 Published online: March 16, 2025 Processing time: 162 Days and 0.1 Hours
Abstract
Sepsis is a life-threatening condition caused by a dysregulated response of the body in response to an infection that harms its tissues and organs. Interleukin-6 (IL-6) is a significant component of the inflammatory response as part of the pathogenesis of sepsis. It aids in the development of Acute lung injury and, subsequently, multiple organ dysfunction syndrome. This letter probes into the correlation between plasma IL-6 levels and the risk of developing acute lung injury and multiple organ dysfunction syndrome in critically ill patients with sepsis. While it shows promising results, limitations like its observational study design, a limited sample size, a single center involvement, single-time-point measurement, and a lack of a control group restrain its cogency. The study is a big step in identifying IL-6 as a biomarker to improve patient care.
Core Tip: The study explores the association of interleukin-6 levels with the risk of developing acute lung injury and multiple organ dysfunction syndrome in critically ill sepsis patients. It underscores its potential as a valuable biomarker for prognosis and guiding treatment in intensive care settings. However, limitations like an observational study design, a limited sample size, a single center involvement, single-time-point measurement, and no control group should be considered in further research.
